Skip to main content

Table 1 Participant characteristics at baseline

From: Providing medication for opioid use disorder and HIV pre-exposure prophylaxis at syringe services programs via telemedicine: a pilot study

 

Enrolled; n = 17

n, (%)

Age

 

 20–29

6 (35%)

 30–39

7 (41%)

 40–49

2 (12%)

 50+

2 (12%)

Racial identity

 

 American Indian/Native American

1 (6%)

 White

14 (82%)

 Other

1 (6%)

 Prefer not to respond

1 (6%)

Ethnicity

 

 Not Latinx

16 (94%)

 Latinx

1 (6%)

Gender identitya

 

 Female

4 (23%)

 Male

13 (77%)

Education completed

 

 Some high school

3 (18%)

 High school or GED

4 (23%)

 Any college

10 (59%)

Relationship status

 

 Single/separated

11 (65%)

 Married/partnered

6 (35%)

Employment

 

 Working full-time

3 (18%)

 Working part-time

5 (29%)

 Student

1 (6%)

 Disabled, unable to work

1 (6%)

 Unemployed

6 (35%)

 Stay at home parent

1 (6%)

Insurance coverage

 

 Private

3 (18%)

 Public

1 (6%)

 None

13 (76%)

Had consistent access at home to

 

 Computer with video camera

6 (35%)

 Computer without video camera

1 (6%)

 Smartphone

17 (100%)

 Tablet

1 (6%)

 Basic telephone (without internet capabilities)

0 (0%)

Had ever taken bup/nx prior to study enrollment

16 (94%)

Was on MOUD (bup/nx or methadone) in prior 12 months

9 (53%)

 Obtained from provider

6 (67%)

 Obtained from informal sourceb

5 (56%)

Had ever overdosed on heroin, fentanyl, or prescription pain medication

9 (53%)

Had heard of PrEP before

12 (71%)

Had ever taken PrEP prior to study enrollment

1 (6%)

Positive for hepatitis C antibodyc

10 (63%)

  1. aOther options available for selection were Transgender Male, Transgender Female, Non-binary/Gender Non-Conforming, and Other
  2. b“Off the street” or “From a friend”
  3. c10/16; unable to draw blood on one participant